Limits...
Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease.

Xu Z, Liu L, Pan X, Wei K, Wei M, Liu L, Yang H, Liu Q - Medicine (Baltimore) (2015)

Bottom Line: In patients with normal ALT levels, serum GP73 concentrations were significantly higher in patients with prominent hepatic inflammatory injury and fibrosis than in patients without hepatic inflammatory injury or fibrosis.Serum GP73 concentrations and GP73 protein expression were decreased in the liver tissues of patients whose ALT levels normalized after 1 year of ETV antiviral therapy.Changes in serum GP73 levels were closely associated with changes in liver injury severity, and, therefore, GP73 may be an effective new liver inflammatory injury biomarker, and could be useful for monitoring the prognosis of chronic HBV infectious patients with normal ALT levels.

View Article: PubMed Central - PubMed

Affiliation: From the Clinical Liver Center (ZX, Liguan Liu, XP, HY, QL); Central Laboratory of Clinical Hepatology (KW, MW); and Department of Pathology (Lifei Liu), The 180th Hospital of the People's Liberation Army, Quanzhou, China.

ABSTRACT
Alanine aminotransferase (ALT) is the most commonly used marker of liver injury, but normal ALT levels are seen in a proportion of chronic hepatitis B virus (HBV)-infected patients with severe liver injury. Golgi protein 73 (GP73) is a promising alternative marker of liver injury. This study assessed the relation between GP73 levels and liver disease severity, monitored the kinetic changes in GP73 levels in chronic HBV patients receiving entecavir (ETV) therapy, and investigated the potential diagnostic and prognostic values of serum GP73 as a new liver injury biomarker in chronic HBV infections. This study enrolled 1150 patients with chronic HBV infections, 200 of whom were retrospectively enrolled in this study after receiving 1 year of ETV treatment. GP73 expression in liver tissue was detected by immunohistochemistry. GP73 levels in single or serial serum samples were measured by enzyme-linked immunosorbent assay. Immunohistochemical analysis indicated that GP73 protein expression in the liver increased progressively with pathologic progression from nonexistent or mild hepatitis to severe hepatitis and cirrhosis during chronic HBV infection. Serum GP73 levels were positively correlated with the disease severity of chronic HBV infections (r = 0.58, P < 0.001). In patients with normal ALT levels, serum GP73 concentrations were significantly higher in patients with prominent hepatic inflammatory injury and fibrosis than in patients without hepatic inflammatory injury or fibrosis. Serum GP73 concentrations and GP73 protein expression were decreased in the liver tissues of patients whose ALT levels normalized after 1 year of ETV antiviral therapy. Changes in serum GP73 levels were closely associated with changes in liver injury severity, and, therefore, GP73 may be an effective new liver inflammatory injury biomarker, and could be useful for monitoring the prognosis of chronic HBV infectious patients with normal ALT levels.

Show MeSH

Related in: MedlinePlus

Distribution of quantitatively detected serum GP73 levels in patients with different severities of HBV-related liver diseases. (A) The concentrations of serum GP73 in 5 groups: control = healthy control; HBV-C = HBV carriers; CHB = chronic hepatitis B; HCC = HBV-related primary hepatocellular carcinoma; LC = hepatitis B liver cirrhosis. (B) Serum GP73 levels in decompensated and compensatory LC. (C) ROC curve for the diagnosis of HCC. (D) ROC curve for the diagnosis of LC. AUC = area under ROC curve, CI = confidence interval, ROC = receiver-operating characteristic.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4554005&req=5

Figure 2: Distribution of quantitatively detected serum GP73 levels in patients with different severities of HBV-related liver diseases. (A) The concentrations of serum GP73 in 5 groups: control = healthy control; HBV-C = HBV carriers; CHB = chronic hepatitis B; HCC = HBV-related primary hepatocellular carcinoma; LC = hepatitis B liver cirrhosis. (B) Serum GP73 levels in decompensated and compensatory LC. (C) ROC curve for the diagnosis of HCC. (D) ROC curve for the diagnosis of LC. AUC = area under ROC curve, CI = confidence interval, ROC = receiver-operating characteristic.

Mentions: We assessed whether there were serum GP73 changes that were associated with liver disease progression from nonexistent or mild to severe hepatitis, and, furthermore, whether serum GP73 changes were associated with chronic hepatitis B complications. We observed that serum GP73 was significantly increased in chronic HBV infection patients when compared with the healthy control group (F = 191.60, P < 0.001). Furthermore, along with increasing necroinflammatory and fibrotic severity, serum GP73 increased with the progression of chronic hepatitis B. Serum GP73 levels were 53.15 ± 22.79 ng/mL in HBV-C, 110.19 ± 66.91 ng/mL in CHB, 195.01 ± 104.22 ng/mL in HCC, and 225.71 ± 99.37 ng/mL in LC. Serum GP73 levels were significantly different between all groups (all P < 0.001, Figure 2A). Pearson correlation analysis showed that there was a positive correlation between changes in the serum GP73 level and liver disease severity in CHB patients (r = 0.58, P < 0.001). Serum GP73 levels in patients with decompensated cirrhosis were much higher than in patients with compensatory cirrhosis (236.78 ± 97.15 ng/mL vs. 166.075 ± 93.38 ng/mL) (P < 0.001, Figure 2B).


Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease.

Xu Z, Liu L, Pan X, Wei K, Wei M, Liu L, Yang H, Liu Q - Medicine (Baltimore) (2015)

Distribution of quantitatively detected serum GP73 levels in patients with different severities of HBV-related liver diseases. (A) The concentrations of serum GP73 in 5 groups: control = healthy control; HBV-C = HBV carriers; CHB = chronic hepatitis B; HCC = HBV-related primary hepatocellular carcinoma; LC = hepatitis B liver cirrhosis. (B) Serum GP73 levels in decompensated and compensatory LC. (C) ROC curve for the diagnosis of HCC. (D) ROC curve for the diagnosis of LC. AUC = area under ROC curve, CI = confidence interval, ROC = receiver-operating characteristic.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4554005&req=5

Figure 2: Distribution of quantitatively detected serum GP73 levels in patients with different severities of HBV-related liver diseases. (A) The concentrations of serum GP73 in 5 groups: control = healthy control; HBV-C = HBV carriers; CHB = chronic hepatitis B; HCC = HBV-related primary hepatocellular carcinoma; LC = hepatitis B liver cirrhosis. (B) Serum GP73 levels in decompensated and compensatory LC. (C) ROC curve for the diagnosis of HCC. (D) ROC curve for the diagnosis of LC. AUC = area under ROC curve, CI = confidence interval, ROC = receiver-operating characteristic.
Mentions: We assessed whether there were serum GP73 changes that were associated with liver disease progression from nonexistent or mild to severe hepatitis, and, furthermore, whether serum GP73 changes were associated with chronic hepatitis B complications. We observed that serum GP73 was significantly increased in chronic HBV infection patients when compared with the healthy control group (F = 191.60, P < 0.001). Furthermore, along with increasing necroinflammatory and fibrotic severity, serum GP73 increased with the progression of chronic hepatitis B. Serum GP73 levels were 53.15 ± 22.79 ng/mL in HBV-C, 110.19 ± 66.91 ng/mL in CHB, 195.01 ± 104.22 ng/mL in HCC, and 225.71 ± 99.37 ng/mL in LC. Serum GP73 levels were significantly different between all groups (all P < 0.001, Figure 2A). Pearson correlation analysis showed that there was a positive correlation between changes in the serum GP73 level and liver disease severity in CHB patients (r = 0.58, P < 0.001). Serum GP73 levels in patients with decompensated cirrhosis were much higher than in patients with compensatory cirrhosis (236.78 ± 97.15 ng/mL vs. 166.075 ± 93.38 ng/mL) (P < 0.001, Figure 2B).

Bottom Line: In patients with normal ALT levels, serum GP73 concentrations were significantly higher in patients with prominent hepatic inflammatory injury and fibrosis than in patients without hepatic inflammatory injury or fibrosis.Serum GP73 concentrations and GP73 protein expression were decreased in the liver tissues of patients whose ALT levels normalized after 1 year of ETV antiviral therapy.Changes in serum GP73 levels were closely associated with changes in liver injury severity, and, therefore, GP73 may be an effective new liver inflammatory injury biomarker, and could be useful for monitoring the prognosis of chronic HBV infectious patients with normal ALT levels.

View Article: PubMed Central - PubMed

Affiliation: From the Clinical Liver Center (ZX, Liguan Liu, XP, HY, QL); Central Laboratory of Clinical Hepatology (KW, MW); and Department of Pathology (Lifei Liu), The 180th Hospital of the People's Liberation Army, Quanzhou, China.

ABSTRACT
Alanine aminotransferase (ALT) is the most commonly used marker of liver injury, but normal ALT levels are seen in a proportion of chronic hepatitis B virus (HBV)-infected patients with severe liver injury. Golgi protein 73 (GP73) is a promising alternative marker of liver injury. This study assessed the relation between GP73 levels and liver disease severity, monitored the kinetic changes in GP73 levels in chronic HBV patients receiving entecavir (ETV) therapy, and investigated the potential diagnostic and prognostic values of serum GP73 as a new liver injury biomarker in chronic HBV infections. This study enrolled 1150 patients with chronic HBV infections, 200 of whom were retrospectively enrolled in this study after receiving 1 year of ETV treatment. GP73 expression in liver tissue was detected by immunohistochemistry. GP73 levels in single or serial serum samples were measured by enzyme-linked immunosorbent assay. Immunohistochemical analysis indicated that GP73 protein expression in the liver increased progressively with pathologic progression from nonexistent or mild hepatitis to severe hepatitis and cirrhosis during chronic HBV infection. Serum GP73 levels were positively correlated with the disease severity of chronic HBV infections (r = 0.58, P < 0.001). In patients with normal ALT levels, serum GP73 concentrations were significantly higher in patients with prominent hepatic inflammatory injury and fibrosis than in patients without hepatic inflammatory injury or fibrosis. Serum GP73 concentrations and GP73 protein expression were decreased in the liver tissues of patients whose ALT levels normalized after 1 year of ETV antiviral therapy. Changes in serum GP73 levels were closely associated with changes in liver injury severity, and, therefore, GP73 may be an effective new liver inflammatory injury biomarker, and could be useful for monitoring the prognosis of chronic HBV infectious patients with normal ALT levels.

Show MeSH
Related in: MedlinePlus